OncoSec Medical Inc represents values of innovation, commitment, and patient-focused care. The company philosophy revolves around advancing novel oncology treatments through its proprietary ImmunoPulse® platform technology. With a strong focus on delivering effective and safe therapies, OncoSec Medical Inc prioritizes patient well-being and aims to improve cancer treatment outcomes. Through strategic collaborations and a dedicated research and development approach, the company strives to redefine the way cancer is treated, offering hope to patients worldwide. OncoSec Medical Inc's commitment to transforming cancer therapy reinforces its position as a leading player in the oncology sector.

OncoSec Medical Inc is primarily present in the United States.

OncoSec Medical Inc has achieved several significant milestones in the field of cancer immunotherapy. The company successfully completed the Phase II OMS Study, demonstrating positive clinical results in patients with metastatic melanoma. They also received FDA Breakthrough Therapy Designation for their lead product candidate, TAVO, which facilitates the local delivery of DNA-based immunotherapies. OncoSec Medical Inc further expanded its pipeline through strategic collaborations with Merck and Roswell Park Comprehensive Cancer Center. The company's dedication to advancing innovative therapies and improving patient outcomes has positioned OncoSec Medical Inc as a key player in the immunotherapy industry.

OncoSec Medical Inc. is a biotechnology company focused on developing innovative immunotherapies to combat cancer. Established in 2011, the company has grown rapidly due to its commitment to pioneering research and development. OncoSec's expertise lies in its proprietary technology platform, ImmunoPulse®, which harnesses the power of electroporation to enhance the delivery of DNA-based immunotherapies directly into the tumor. By leveraging this cutting-edge approach, OncoSec aims to revolutionize cancer treatment and improve patient outcomes. With a strong emphasis on clinical trials and strategic partnerships, OncoSec continues to make significant strides in the field of oncology.

The main competitors of OncoSec Medical Inc in the market include companies like Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, Genentech, Inc., and Amgen Inc. These pharmaceutical giants operate in the same healthcare sector, specializing in oncology and immunotherapy. While OncoSec Medical Inc focuses on developing innovative and effective cancer treatments, it faces competition from these established players who also strive to provide cutting-edge advancements in the field.

OncoSec Medical Inc is primarily active in the biotechnology and healthcare industries.

The business model of OncoSec Medical Inc focuses on developing innovative immunotherapy treatments for cancer patients. By leveraging its proprietary technology, OncoSec aims to empower the body's immune system to effectively target and destroy tumor cells. The company's comprehensive approach includes utilizing electroporation to enhance the delivery of DNA-based immunotherapies directly into the tumor. By doing so, OncoSec seeks to provide patients with potential solutions that are both safe and effective in combating various types of cancer. Through ongoing research and development, OncoSec Medical Inc strives to revolutionize cancer treatment and improve patient outcomes.

OncoSec Medical KGV ir -0,00.

OncoSec Medical KUV ir 0,00.

AlleAktien kvalitātes vērtējums OncoSec Medical ir 4/10.

gaidāmā OncoSec Medical apgrozījums ir 8,54 milj. USD.

gaidāmā OncoSec Medical peļņa ir -19,67 milj. USD.

OncoSec Medical Inc is a leading company in the field of immuno-oncology therapy. Based in San Diego, California, the company aims to develop a novel class of cancer treatments that specifically activate the patient's own immune system, potentially leading to healing effects. OncoSec Medical's core business involves the research, development, and commercialization of immune-dominant therapy approaches based on the innovation of electroporation technology. This technology uses electrical pulses to enhance the delivery of therapeutic agents into tumor cells, resulting in more targeted and effective therapeutic outcomes. The flagship product of OncoSec Medical is the ImmunoPulse System, a groundbreaking therapy that synergistically combines electroporation and immunity to generate coordinated anti-tumoral immune responses. The system provides a fast, highly effective, and safe treatment option that has a positive impact on the survival of patients with advanced skin cancer. ImmunoPulse is capable of treating both primary and metastatic tumors and has the potential to be used in many other cancer types. In addition to ImmunoPulse, OncoSec Medical also offers other innovative therapy approaches such as the DNA plasmid vector system. This system aims to inhibit the rheostat function of tumor cells in the growth factor signaling pathway, thereby inhibiting tumor growth. OncoSec Medical also has a pipeline of products, including OMS-776, an agonist of Toll-like receptors that is capable of enhancing the immune response to the tumor microenvironment, and OMS-905, an immunosuppressive drug that improves T-cell regulation in cancer patients. OncoSec Medical is an innovative company that collaborates closely with leading scientists and research partners to develop the next generation of cancer treatments. The company is committed to revolutionizing the way cancer is treated and improving the lives of patients worldwide. With its unique approach and strong pipeline of products, OncoSec Medical is well positioned to meet the evolving needs of patients and providers in the field of cancer treatment. In summary, OncoSec Medical's business model consists of a combination of research, development, and commercialization of immuno-oncology therapies based on innovative electroporation technology. The company offers a wide range of products, including the ImmunoPulse system, DNA plasmid vectors, and drug candidates such as OMS-776 and OMS-905. With its strong pipeline of products and vision to revolutionize cancer treatment, OncoSec Medical is an exciting and promising company that plays a prominent role in cancer research and treatment.

OncoSec Medical izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt OncoSec Medical vai uzņēmums nedod dividendes.

OncoSec Medical ISIN ir US68234L3069.

OncoSec Medical WKN ir A2PKW3.

OncoSec Medical simbols ir ONCS.

Pēdējo 12 mēnešu laikā OncoSec Medical maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos OncoSec Medical plāno maksāt dividendes 0 USD apmērā.

OncoSec Medical pašreizējā dividendu rentabilitāte ir .

OncoSec Medical maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

OncoSec Medical pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

OncoSec Medical tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu OncoSec Medical apmērā 0 USD, kas tika izmaksāta 1.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.08.2024..

Pēdējās dividendes izmaksa notika 1.08.2024..

Gadā 2023, OncoSec Medical izmaksāja 0 USD dividendes.

OncoSec Medical dividendes tiek izmaksātas USD.